Enrico Martin

165 Emerging therapeutic targets Table 1 Continued. Author, year Model Regimen Pathway Tissue NF1 a Outcome Growth b Survival c Metastasis d Cytoplasmic targets Hirokawa, 2006 XM Sichuan PAK1 S462 NF1 NA NA Johannessen, 2008 GEMM Sirolimus mTOR NPcis NA NA NA Demestre, 2009 XM Bio 30 + CAPE PAK1 S462 NF1 NA Lee, 2009 XM OSU03012 PDK1 HMS-97 S NA NA Qi, 2009 XM Saposin C protein Lysosomes STS26T S NA NA Banerjee, 2010 XM Cucurbaticin-1 STAT3 ST88-14 NF1 NA NA Bhola, 2010 XM Sirolimus mTOR NA NF1 NA NA De Raedt, 2011 GEMM Sirolimus + IPI-504 mTOR, Hsp90 NPcis NA NA Ghadimi, 2012 XM Voxtalisib + chloroquine PI3K, mTOR, autophagy MPNST724 S NA NA STS26T S NA Dodd, 2013 GEMM PD0325901 MEK NF1 fl/fl ; Ink4a/Arf fl/fl NA NA NA Jessen, 2013 XM PD0325901 MEK S462TY NF1 NA Brundage, 2014 XM Everolimus mTOR S462TY NF1 NA NA De Raedt, 2014 GEMM PD0325901 + JQ1 MEK, BET NPcis; SUZ12 -/- NA NA NA NPcis NA NA NA Malone, 2014 GEMM Sirolimus + PD0325901 mTOR, MEK NPcis NA NA NA Watson, 2014 GEMM Everolimus + PD0325901 mTOR, MEK NF1 fl/fl ; Pten fl/fl NA NA NA Pten fl/fl ; EGFR NA NA NA Wu, 2014 XM FLLL32 JAK2/STAT3 S462TY NF1 NA NA Yamashita, 2014 XM Everolimus + bortezomib mTOR, proteasome NF90.8 NF1 NA NA Slotkin, 2015 XM Sapanisertib + sirolimus mTOR MPNST NA NA NA Kendall, 2016 XM PD0325901 MEK S462TY NF1 NA Sweeney, 2016 AA PD0325901 + PTT MEK M2 NA NA 7